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1. Introduction
Cardiac disease in pregnancy is a leading cause of maternal and neonatal morbidity and
mortality [1]. Pregnancy not only poses a risk of maternal mortality but also of serious
morbidity such as heart failure, stroke and cardiac arrhythmias. Heart failure during preg‐
nancy was recognized as early as 19th century [2], however, the syndrome was not recognized
as a distinct clinical entity until the 1937, when Gouley et al. [3] described the clinical and
pathologic features of seven pregnant women who had severe and often fatal heart failure. In
1971, Demakis et al. [4] described 27 patients who presented during the puerperium with
cardiomegaly, abnormal electrocardiographic findings, and congestive heart failure, and
named the syndrome peripartum cardiomyopathy (PPCM). The European Society of Cardi‐
ology [5] recently defined peripartum cardiomyopathy as an idiopathic cardiomyopathy
presenting with heart failure secondary to left ventricular systolic dysfunction towards the
end of pregnancy or in the months following delivery, where no other cause of heart failure is
found. It is a diagnosis of exclusion. The left ventricle may not be dilated but the ejection
fraction is nearly always reduced below 45%.
The etiology of this disease remains uncertain, but a number of possible causes of PPCM have
been proposed [5], including myocarditis, abnormal immune response to pregnancy, malad‐
aptive response to the hemodynamic stress of pregnancy, stress activated cytokines, viral
infection, and prolonged tocolysis. In addition, there have been a few reports of familial PPCM
[6 - 8], raising the possibility that some cases of PPCM are actually familial dilated cardiomy‐
opathy unmasked by pregnancy. Overall, there is more evidence to support myocarditis or an
autoimmune process as the cause of the disease than for other proposed etiologies.
The beginning of the myocarditis hypothesis is related to work of Gouley et al. [3], who
reported several cases of heart failure in women dying in the puerperium. Also, they found
enlarged hearts with focal areas of necrosis and fibrosis and they also proposed infection as a
© 2013 Deljanin Ilic and Simonovic; licensee InTech. This is an open access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
possible cause of heart failure in these women. After that, Melvin and colleagues proposed
myocarditis as the cause for PPCM and reported a dense lymphocyte infiltrate with variable
amounts of myocyte oedema, necrosis, and fibrosis in right ventricular biopsy specimens. They
also noted that treatment with prednisone and azathioprine resulted in clinical improvement
and loss of inflammatory infiltrate on repeated biopsies in the three patients studied [9,10].
Rizeq et al. [11] also found an inflammatory component in less than 10% of biopsy samples
from patients with PPCM, a proportion similar to that found in age-and-sex-matched patients
with idiopathic dilated cardiomyopathy. The highest frequency of myocarditis (78%) was
reported by Midei et al., who found 14 of the 18 patients to have borderline and/or established
histologic myocarditis. In that study resolution of myocarditis was associated with improved
left ventricular function in the post-partum period [12]. A decade later, Felker and colleagues
[13] confirmed that the absence or presence of inflammation on endomyocardial biopsy tissue
did not predict outcome in patients with PPCM. However in that endomyocardial biopsy
study, the authors also showed a high incidence of active viral myocarditis, using the Dallas
criteria, in 26 of 51 PPCM patients. Bultmann et al. [14] found that after a viral infection, a
pathologic immune response might occur that is inappropriately directed against native
cardiac tissue proteins, leading to ventricular dysfunction. However, in that study the same
incidence and types of viral positivity were noted also in controls.
Why should myocarditis be more common in pregnancy? It is assumed that the amended or
muted immune response during pregnancy allows viral replication and greater likelihood of
myocarditis in the setting of a viral infection [15]. Also it is known that pregnancy results in
an immuno compromised state and that the decreased humoral and cellular immunity in
pregnancy, together with higher levels of corticosteroids, and raised titres of ‘blocking
antibodies’ formed in normal pregnancy, may allow greater viral replication than in age-
matched non-pregnant individuals, and thus, a greater probability of viral myocarditis in the
context of infection [16,17].
Farber and Glasgow [16] in their animal studies demonstrated that pregnant mice are more
susceptible to viral infections than non-pregnant ones. Furthermore, they found that these
viruses multiply to a greater level in the hearts of pregnant mice. The physiologic and
hemodynamic changes of pregnancy may result in an increased susceptibility to viral myo‐
carditis, higher virus load (such as coxsackie and echoviruses), and worsening of myocardial
viral lesions [16, 17]. Pregnancy may predispose women to a more severe form of viral
myocarditis when they are infected by a cardiotropic virus [18]. Immunologic studies in
women have demonstrated enhanced suppressor cell activity during pregnancy [19], which
could augment susceptibility to viral infections [20, 21].
2. Pathogenesis
2.1. Infection
Myocarditis is the term used to indicate acute infective, toxic or autoimmune inflammation of
the heart [22]. It can be caused by many different viruses and the microbial pathogenesis may
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be complex. Myocardial inflammatory reaction can be directed against the specific virus
infection or predominantly reflects local autoimmune processes. Probably combination of
autoimmune processes and virus-associated pathogenicity determines the outcome of the
disease. A wide spectrum of agents has been associated with myocarditis, and the more
common of these are listed in Table 1.
Etiology Examples
Infectious Adenovirus, Coxsackievirus, Cytomegalovirus, Epstein–Barr virus, HIV-1, Borrelia
(Lyme’s disease), Toxoplasmosis, Actimonices, Chlamydia, Coxiella burneti,
Echinococcus granulosus
Drug induced Amphetamines, Anthracyclines (especially doxorubicin), Catecholamines,
Cocaine, Cyclophosphamid, Trastuzumab
Systemic diseases
(autoimmune disease)
Crohn’s disease, Kawasaki disease, Sarcoidosis, Ulcerative colitis, Cardiac
rejection, Peri-partum myocarditis, Giant cell myocarditis, Systemic lupus
erythematosus, Dermatomyositis
Hypersensitivity to drugs Hydrochlorothiazide and loop diuretics, Methyldopa
Penicillin, Ampicilin, Sulphadiazine, Sulphamethoxazole
HIV - human immunodeficiency virus
Table 1. Common etiology of myocarditis
During the acute viremic stage, viral replication can be present, in the absence of significant
host immune responses. Viruses can enter the cardiac myocytes, fibroblasts, or endothelial
cells through receptor-mediated endocytosis. Acute myocardial injury can result from either
direct virus-mediated lytic processes or is caused by the emerging antiviral immune response.
In fulminant cases of myocarditis, resulting myocyte necrosis may cause a significant loss of
contractile tissue, which is accompanied by rapidly developing heart failure and early death
of the host. It seems that the virus enters cardiomyocytes or macrophages via specific receptors
and coreceptors. For example, a receptor for the coxsackie and adenoviruses 2 and 5 is the
coxsackie adenoviral receptor [23]. Coreceptor has a role in serotypes B1, B2, and B5, and it is
estimated that this activation may play a role of coreceptor acceleration and can cause an
increase in virulence of Coxsackie virus B3. Virulence of Coxsackie virus B3 depends on the
viral genome, as well as a host of factors, which may be increased by deficient levels of selenium
or copper [24]. During the second stage of infection initial immune response is essential in
defending the body during early infection. Natural killer cells and macrophages cause cytokine
production (tumor necrosis factor-α, interleukin-1, interleukin-2, and interferon gamma) and
inflammatory cell infiltration of the myocardium. The third stage consists of fibrotic reparation
and cardiac dilatation in the presence or absence of low-level persistent viral genomes [25].
Important place of myocarditis pathogenesis belongs to the mechanism of molecular mimicry,
which means that the activated T killer cells are not just attacking viruses and viral antigens,
but they can function on their own proteins, in this case myosin. Further activation of B cells
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leads to production of specific antibodies as a central place in the subacute and chronic phase
of myocarditis. This leads to further necrosis, fibrosis, cardiac remodeling, dilatation, and
chronic heart failure ( figure 1).
Figure 1. Transition from inflammation to cardiomyopathy
Because of the myocarditis-like inflammatory response seen in endomyocardial biopsy
specimens (EMBs) from patients with PPCM, a possibility is reactivation of latent virus
infection as a consequence of impaired immune mechanisms during pregnancy [26]. However,
no investigation regarding the prevalence of viral genomes in PPCM has been published until
recently, when endomyocardial biopsy specimens from 26 patients with PPCM revealed viral
genomes (parvovirus B19, human herpes virus 6, Epstein–Barr virus, and human cytomega‐
lovirus) in 8 patients (30.7%) that were associated immunohistologically with interstitial
inflammation [14]. The presence of viral genomes in EMBs was associated with inflammatory
cardiomyopathy exclusively in patients with PPCM but not in control subjects. Bachmaier et
al. [27] reported experimental data supporting the Chlamydia hypothesis. A peptide from the
murine heart muscle-specific alpha myosin heavy chain that has sequence homology to the
60-kDa cysteine-rich outer membrane proteins of Chlamydia pneumoniae, Chlamydia psittaci
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and Chlamydia trachomatis was shown to induce autoimmune inflammatory heart disease in
mice. Injection of the homologous Chlamydia peptides into mice also induced perivascular
inflammation, fibrotic changes and blood vessel occlusion in the heart. Chlamydia DNA
functioned as an adjuvant in the triggering of peptide-induced inflammatory heart disease. In
the study of Cenac et al. [28], 96% of patients with PPCM versus 80% of controls were positive
for Chlamydia IgG antibodies.
3. Autoimmune mechanisms
The introduction of fetal cells of hematopoietic origin into the maternal circulation may have
a significant influence on the immune and genetic alterations. In women with PPCM, high
titers of autoantibodies against select cardiac tissue proteins (adenine nucleotide translocator,
branched chain α-keto acid dehydrogenase) and increased levels of tumor necrosis factor-
alpha, interleukin- 6, and soluble Fas receptors (an apoptosis signaling receptor) have been
reported, suggesting a possible role of abnormal immunologic activities and inflammatory
cytokines in pathogenesis of this disease [29-31].
The serum from women with peripartum cardiomyopathy has been found to contain autoan‐
tibodies in high titers, which are not present in serum from patients with idiopathic cardio‐
myopathy [32]. Most of these antibodies are against normal human cardiac tissue proteins of
37, 33, and 25 kD. The peripheral blood in these patients has a high level of fetal microchimer‐
ism in mononuclear cells, an abnormal cytokine profile, and low levels of CD4+ CD25lo
regulatory T cells. Some authors postulated that after delivery the fast degeneration of the
uterus results in fragmentation of tropocollagen by collagenolytic enzymes releasing actin,
myosin, and their metabolites [33]. Antibodies are formed against actin that cross-react with
the myocardium, and the patient subsequently has a cardiomyopathy.
4. Prevalence and clinical features
The prevalence of acute peripartum myocarditis is unknown because most cases are not
recognized on account of non-specific, only mild, or no symptoms, but sudden death may
occur [22]. The clinical manifestations of myocarditis are various. Myocarditis may develop as
a complication of an upper respiratory or gastrointestinal infection with general symptoms,
particularly fever and skeletal myalgia, malaise, and anorexia. Since myocarditis may not
develop for several days or weeks after symptoms and after return to a normal activity, there
is a risk of overexertion, which may be dangerous. Arrhythmias or conduction disturbances
may be life threatening despite only mild focal injury, whereas more widespread inflammation
is necessary before cardiac dysfunction can cause symptoms.
The initial presentation may be with heart failure or suspected acute myocardial infarction.
Acute onset of chest pain is usual and may mimic myocardial infarction or be associated with
pericarditis. Symptoms resembling those of heart failure such as dyspnea, dizziness, ankle
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edema, and orthopnea can occur even in normal pregnancies. Therefore, a pregnant woman
in whom peripartum myocarditis and/or cardiomyopathy is developing may consider her
symptoms to be normal. If swelling and other heart failure symptoms develop suddenly in an
otherwise normal pregnancy, this should prompt further investigation.
5. Investigations
The initial evaluation of acute peripartum myocarditis includes detailed history and careful
physical examination.
The ECG is not specific for diagnosis, but it may show sinus tachycardia, focal or generalised
abnormalities, ST-segment elevation, fascicular blocks or atrioventricular conduction distur‐
bances [34]. Although the ECG abnormalities are non-specific, an abnormal ECG maydraw
attention to the heart and lead to other investigations.
The chest x ray may be normal, or show cardiac enlargement, pulmonary venous congestion
or pleural effusions.
There is no specific serum marker for myocarditis. Laboratory tests may show leukocytosis,
elevated erythrocyte sedimentation rate, eosinophilia, or an elevation in the cardiac fraction
of creatine kinase. Evidence of myocyte necrosis may be found with an increase in creatine
kinase or appearance of troponin, indicating myocytolysis. The highest enzyme concentrations
occur early and will probably have returned to normal by about a week after onset [35].
Cardiac autoantibodies can be demonstrated only late in the disease process, and a viral origin
of myocarditis can only be proved if the virus is detected within an altered myocardium. Levels
of BNP do not change significantly during normal pregnancy or in the postpartum period, but
are markedly elevated in patients with peripartum cardiomyopathy [36]. So, an early meas‐
urement of BNP could help in detection of systolic dysfunction and elevation of left ventricle
end-diastolic pressure.
Echocardiography may reveal segmental or generalised wall motion abnormalities, left
ventricular dilatation, or a pericardial effusion. Echocardiography allows other causes of heart
failure to be excluded but pronounced focal changes in wall motion may lead to confusion
with myocardial infarction, especially if the ECG changes also suggest this [37]. The advent of
novel echocardiographic techniques provides the opportunity to study peripartum myocar‐
ditis further. These techniques include those for studying ventricular long-axis function, right
ventricular function, tissue Doppler techniques including strain and strain rate echocardiog‐
raphy, and speckle tracking echocardiography. New echo technologies, mainly three-dimen‐
sional echocardiography (3DE) and speckle tracking echocardiography, have become available
and are competitive with cardiac magnetic resonance imaging (MRI) in accuracy while being
less expensive and more widely available [38]. Unfortunately, these novel techniques have not
been widely utilized to study peripartum myocarditis and PPCM.
Cardiac magnetic resonance imaging has been recently developed for the diagnosis of
myocarditis. It allows more accurate measurement of chamber volumes and global and
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segmental myocardial function than echocardiography has a higher sensitivity for the
detection of LV thrombus [39], and it can characterize the myocardium [40]. In suspected
myocarditis MRI can localize and quantify tissue injury, including edema, hyperemia, and
fibrosis. In recent series of 82 patients with myocarditis who had biopsy-proven disease, MRI
alone made the correct diagnosis in 80% cases [41].There are limited data during organogenesis
available, but MRI is probably safe, especially after the first trimester [42].
In the acute phase, the use of contrast media such as gadolinium-diethylene triamino pentaace‐
tic acid (gadolinium-DTPA) helps to differentiate accurately healthy from inflamed or injured
tissue. Furthermore, delayed contrast enhancement with gadolinium can help differentiate the
type of myocyte necrosis: myocarditis vs ischemia. Myocarditis has a nonvascular distribu‐
tion in the subepicardium with a nodular or band-like pattern, whereas ischemia has a vascu‐
lar distribution in a subendocardial or transmural location [43]. Gadolinium can be assumed to
cross the fetal blood–placental barrier, but data are limited. The long-term risks of exposure of
the developing fetus to free gadolinium ions are not known, and therefore gadolinium during
pregnancy should be avoided, but after delivery it represents a useful method for myocarditis
diagnosis. Breast feeding does not need to be interrupted after administration of gadolinium
[44,45] The importance of MRI is the fact that it is a non-invasive method, there is no risk unlike
endomyocardial biopsy, and it can be used to monitor the effects of therapy.
The diagnostic gold standard is endomyocardial biopsy (EMB) with the histological Dallas
criteria [46, 47] in conjunction with the new tools of immunohistochemistry and viral poly‐
merase chain reaction (PCR). EMB and PCR are particularly important for those patients who
are not experiencing improvement in the early weeks after the diagnosis and therapy, since
emerging new antiviral and immunomodulatory treatments depend upon knowing if virus is
present or absent in cardiac tissue. It is recommended that MRI should be performed before
taking tissue samples, to reduce the sampling error. Leurent et al. [48] advocate using cardiac
MRI to guide biopsy to the abnormal area, which may be much more useful than blind biopsy.
Whether endomyocardial biopsy should be done in the setting of peripartum myocarditis is
still controversial. Some authors not recommend it [49, 50] while Midei et al. [12] recommend
endomyocardial biopsy of all patients with peripartum cardiomyopathy and myocarditis who
fail to normalize left ventricular function after one week of standard medical therapy.
6. Management
The most important thing in treatment planning is clinical status of the mother and the fetus.
If the patient is haemodynamically stable vaginal delivery should be carried out. Urgent
delivery irrespective of gestation duration should be considered in women with advanced
heart failure and haemodynamic instability despite treatment. Caesarean section is recom‐
mended with combined spinal and epidural anaesthesia. An experienced interdisciplinary
team is required (cardiologist, obstetrician, anaesthesiologist, neonatologist and intensive care
physician) [51].
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Heart failure should be treated according to guidelines on heart failure [52], and it can be
divided into supportive (heart failure therapy, heart rhythm disturbances, cardiogenic
shock), and specific therapy (immunosuppressive therapy, interferon, immunoglobulin, im‐
mune-adsorptive therapy, immune-modulation). Heart failure therapy involves administra‐
tion of diuretics, vasodilators, inotropes, beta blockers, angiotensin-converting enzyme
inhibitors (ACEI), angiotensin II receptor blockers (ARBs), anticoagulation therapy, and me‐
chanical support with intraaortic balloon pump or ventricular assist devices in cardiogenic
shock as a bridge to recovery or heart transplantation. During pregnancy, ACEI, ARBs and
renin inhibitors are contraindicated because they can cause birth defects, although they are
the main treatment for postpartum women with heart failure [53, 54]. Digoxin, beta-block‐
ers, loop diuretics, and drugs that reduce afterload such as hydralazine and nitrates have
been proven to be safe and are the mainstays of medical therapy of heart failure during
pregnancy [15, 55]. Warfarin can cause spontaneous fetal cerebral hemorrhage in the second
and third trimesters and therefore is generally contraindicated during pregnancy [56].
7. Specific therapy
In case of early stages of myocarditis, administration of antiviral medications that target vi‐
ral attachment to host-cell receptors, virus entry, or virus uncoating, would be effective.
Interferon beta. It was shown that beta interferon can decrease the number of viruses up to
complete regression, the accumulation of viral RNA and viral coat protein. Interferon beta
(IFN-β1a) may affect the elimination of viruses, repair left ventricular ejection fraction and
clinical status of patients [57]. In the study of Schmidt-Luce et al. [58], parvovirus B19 and
human herpes virus-6 responded less well upon IFN-β treatment with respect to virus clear‐
ance and hemodynamic changes, although affected patients can improve clinically, despite
incomplete virus clearance following reduction of virus load and/or improvement of endo‐
thelial dysfunction. Complete clearance of those viruses may need longer treatment, higher
doses, or even change of the antiviral treatment regimens. Currently, there is no approved
treatment for chronic viral heart disease, but data have demonstrated that subgroups of pa‐
tients who had not improved upon regular heart failure medication may get significant ben‐
efit even years after onset of chronic disease.
Immunosuppressive therapy. It could be considered in patients with proven myocarditis.
Administration of immunosuppressive (corticosteroids, azathioprine, cyclosporine) is still
controversial and investigators have emphasized the need to rule out viral infection before
starting immunosuppressive treatment, as the treatment may activate a latent virus, with
subsequent deterioration in myocardial function [59]. In published randomized study on the
Tailored Immunosuppression in Inflammatory Cardiomyopathy (TIMIC study) authors con‐
firmed a positive treatment response in patients with chronic active myocarditis [60]. Ac‐
cording to studies performed until now, immunosuppressive therapy should not be
routinely administered to patients with myocarditis. However, patients with giant cell myo‐
carditis, autoimmune or hypersensitive myocarditis with heart failure can benefit from this
therapy. The best responders may be those with active autoimmune response without per‐
sisting viral genome [61].
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Immunoglobulin. In case of autoimmune myocarditis, inflammatory process in the myocar‐
dium is triggered by a transient viral infection. Instead of anticytokine or immune-suppression
therapy, a possible strategy is passive immunization through the infusion of immune globu‐
lins. Bozkurt and colleagues added intravenous immune globulin to conventional heart failure
therapy in 6 women with PPCM and reported a significantly greater improvement in left
ventricular ejection fraction compared with 11 control patients who received conventional
therapy alone. Although the results seemed encouraging, a very small number of patients and
the lack of a blindly randomized, well-matched control group limited the study [62]. However,
McNamara et al. [63] reported that improvement of left ventricular ejection fraction was
identical in both the intravenous immuneoglobulin treatment arm and in the placebo arm.
These results suggest that for patients with recent-onset dilated cardiomyopathy, immuno‐
globulins do not improve left ventricular ejection fraction. There are no reliable data for the
application of this type of therapy in the adult population with viral myocarditis who do not
respond to immunosuppressive therapy [61].
Adsorptive immune therapy. Involves the use of plasmapheresis to remove circulating
cytokines and antibodies to cardiomyocytes, beta-adrenergic receptors, adenosintriphosphate
carriers, myosin. If this treatment is applied five or more days, beside elimination of circulating
antibodies and immune complexes, it also effects the elimination from the heart muscle.
Removal of circulating antibodies by immunoadsorption improved cardiac function and
clinical and humoral markers of heart failure severity (NT-proBNP) [64]. Immunoadsorption
can also decrease myocardial inflammation, and in patients with inflammatory cardiomyop‐
athy, left ventricular systolic function improved after protein A immunoadsorption [65]. The
value of adsorptive immune therapy should be confirmed in larger studies.
Monoclonal antibodies. There are some data about possible use of monoclonal antibodies in
myocarditis due to T-cell mediated inflammation. Wang et al. [66]. showed that administration
of anti-CD4 monoclonal antibody can induce immune tolerance to porcine cardiac myosin.
Cardiac function of antibody-treated rats was significantly increased compared with untreated
rats 18 days postimmunization examined by transthoracic echocardiography. Also, antibody-
treated rats had no proliferative response to porcine cardiac myosin examined by lymphocyte
proliferation assay, and administration of anti-CD4 monoclonal antibody significantly
prevented production of anti-cardiac myosin antibodies. The conclusion of that study was that
immune tolerance to cardiac myosin could be induced by anti-CD4 monoclonal antibody in
vivo, and cardiac dysfunction and myocardial injury could be prevented by induction of
immune tolerance.
8. Prognosis
Recovery from acute myocarditis often surprises and delights after life threatening illness.
Clinical recovery may be slow and delayed even up to a year or more after delivery. Even
when it appears to be complete, a portion of cardiovascular reserve has been lost, as is indicated
by the myocytolysis found on biopsy [22]. It is also uncertain how many patients will progress
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to cardiomyopathy. Recurrence in future pregnancies is not invariable, but there are few data.
Pregnancy should therefore be discouraged in any woman with residual myocardial dysfunc‐
tion or, if possible, delayed for some years.
9. Summary
Myocarditis is an inflammatory disease of the myocardium that is diagnosed by histological,
immunological and immunochemical criteria, and is associated with cardiac dysfunction.
There has been greater evidence for myocarditis as a cause of PPCM than any other proposed
aetiological factor. The prevalence of acute peripartum myocarditis is unknown because most
cases are not recognized on account of non-specific, only mild, or no symptoms, but sudden
death may occur. However, the initial presentation may be with acute or chronic heart failure
or mimics acute myocardial infarction. The combination of biomarkers from blood samples
together with imaging techniques such as echocardiography and MRI may help to confirm the
diagnosis of myocarditis.The diagnostic gold standard is endomyocardial biopsy with the
histological Dallas criteria in conjunction with the new tools of immunohistochemistry and
viral polymerase chain reaction. Whether endomyocardial biopsy should be done in the setting
of peripartum myocarditis is still an open question. The most important thing in treatment
planning is clinical status of the mother and the fetus. Heart failure in postpartum women
should be treated according to guidelines on heart failure. Pregnant women should not receive
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or warfarin because
of potential teratogenic effects. Specific therapy strategies may include: immunosuppressive
therapy, interferon, immunoglobulin, immune-adsorptive therapy, immune-modulation.
Subsequent pregnancies carry a high risk of relapse, even in women who have fully recovered
left ventricular function.
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